keyword
MENU ▼
Read by QxMD icon Read
search

Tissue plasminogen activator

keyword
https://www.readbyqxmd.com/read/29052571/susceptibility-weighted-imaging-in-thrombolytic-therapy-of-acute-ischemic-stroke
#1
REVIEW
Lin Li, Ming-Su Liu, Guang-Qin Li, Yang Zheng, Tong-Li Guo, Xin Kang, Mao-Ting Yuan
OBJECTIVE: To provide a comprehensive and latest overview of susceptibility-weighted imaging (SWI) in the application of thrombolysis in acute ischemic stroke, and to update the decision-making effect and clinical value of SWI on identifying stroke patients suitable for thrombolytic therapy and possible benefits and risks followed. DATA SOURCES: Literatures referred to this review were collected from PubMed, Medline, and EMBASE published till May 2017, using the search terms including susceptibility-weighted imaging, gradient-echo, T2*, thrombolysis, recombinant tissue plasminogen activator (rt-PA), thrombolytic therapy, and stroke...
October 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/29047259/the-candidate-tumor-suppressor-gene-slc8a2-inhibits-invasion-angiogenesis-and-growth-of-glioblastoma
#2
Mingqi Qu, Ju Yu, Hongyuan Liu, Ying Ren, Chunxiao Ma, Xingyao Bu, Qing Lan
Glioblastoma is the most frequent and most aggressive brain tumor in adults. Solute carrier family 8 member 2 (SLC8A2) is only expressed in normal brain, but not present in other human normal tissues or in gliomas. Therefore, we hypothesized that SLC8A2 might be a glioma tumor suppressor gene and detected the role of SLC8A2 in glioblastoma and explored the underlying molecular mechanism. The glioblastoma U87MG cells stably transfected with the lentivirus plasmid containg SLC8A2 (U87MG-SLC8A2) and negative control (U87MGNC) were constructed...
October 17, 2017: Molecules and Cells
https://www.readbyqxmd.com/read/29044967/comparison-of-long-term-outcomes-of-50-mg-and-100-mg-rt-pa-in-the-management-of-acute-pulmonary-thromboembolism
#3
Elif Yilmazel Ucar, Omer Araz, Bugra Kerget, Nafiye Yilmaz, Metin Akgun, Leyla Saglam
BACKGROUND: Pulmonary thromboembolism (PTE) is a life-threatening disease. In this study, we aimed to evaluate long-term outcomes of the use of 50 mg recombinant tissue-type plasminogen activator (rt-PA) in the management of PTE in terms of relapse, pulmonary hypertension (PH), mortality and hemorrhage, and to compare with the use of 100 mg rt-PA. METHODS: The study was designed as a retrospective cohort. Patients who were diagnosed as acute PTE and received either 50 mg or 100 mg rt-PA in a tertiary care hospital between 2010 and 2015 were included in the study...
October 17, 2017: Clinical Respiratory Journal
https://www.readbyqxmd.com/read/29039441/rivaroxaban-attenuates-thrombosis-by-targeting-the-nf-%C3%AE%C2%BAb-signaling-pathway-in-a-rat-model-of-deep-venous-thrombus
#4
Junhao Ma, Xinxi Li, Yang Wang, Zhenwei Yang, Jun Luo
Anticoagulant therapy is commonly used for the prevention and treatment of patients with deep venous thrombus. Evidence has shown that rivaroxaban is a potential oral anticoagulant drug for the acute treatment of venous thromboembolism. However, the rivaroxaban-mediated molecular mechanism involved in the progression of deep venous thrombosis has not been investigated. In the present study, we investigated the efficacy of rivaroxaban and the underlying signaling pathways in the prevention and treatment of rats with deep venous thrombosis...
September 29, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/29034235/coagulofibrinolytic-changes-in-patients-with-post-cardiac-arrest-syndrome
#5
REVIEW
Takeshi Wada
Whole-body ischemia and reperfusion due to cardiac arrest and subsequent return of spontaneous circulation constitute post-cardiac arrest syndrome (PCAS), which consists of four syndromes including systemic ischemia/reperfusion responses and post-cardiac arrest brain injury. The major pathophysiologies underlying systemic ischemia/reperfusion responses are systemic inflammatory response syndrome and increased coagulation, leading to disseminated intravascular coagulation (DIC), which clinically manifests as obstruction of microcirculation and multiple organ dysfunction...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/29033031/the-next-challenges-for-optimal-reperfusion-in-the-era-of-mechanical-thrombectomy
#6
REVIEW
M Mazighi
The therapeutic management of acute ischemic stroke has changed tremendously over the past few years. Mechanical thrombectomy in addition to intravenous tissue plasminogen activator (t-PA) is currently the standard of care for patients experiencing acute ischemic stroke as a consequence of large vessel occlusion of the anterior circulation. Yet, despite strong evidence supporting such a therapeutic approach, several issues remain a source of debate, such as the need for intravenous t-PA, the optimal target for blood pressure levels and the opportunity for additional antithrombotic therapies to improve reperfusion...
October 12, 2017: Revue Neurologique
https://www.readbyqxmd.com/read/29029706/pulmonary-embolism-in-2017-how-we-got-here-and-where-are-we-going
#7
Geno J Merli
In the 1970s, both the Urokinase Pulmonary Embolism and Urokinase-Streptokinase Pulmonary Embolism trials began the quest to develop thrombolytic therapy for the treatment of acute massive and submassive pulmonary embolism (PE). The goals of these studies were the immediate reduction in clot burden, restoration of hemodynamic stability, and improved survival. Major bleeding became the major barrier for clinicians to employ these therapies. From 1980s to the present time, a number of studies using recombinant tissue-type plasminogen activator for achieving these same above outcomes were completed but major bleeding continued to remain an adoption barrier...
September 2017: Techniques in Vascular and Interventional Radiology
https://www.readbyqxmd.com/read/29027122/hi1a-as-a-novel-neuroprotective-agent-for-ischemic-stroke-by-inhibition-of-acid-sensing-ion-channel-1a
#8
Yandong Ren, Chengchong Li, Jinlong Chang, Rui Wang, Yuhua Wang, Xiang-Ping Chu
Strokes are the second-leading cause of death worldwide, and the cellular and molecular mechanisms underlying stroke-induced brain damage are still uncertain. The present therapy for acute ischemic stroke is limited to thrombolysis with the recombinant tissue plasminogen activator (rtPA). However, rtPA has a narrow therapeutic timeframe of 3-4.5 h, and only approximately 5% of stroke patients can benefit from rtPA treatment. Neuroprotective agents, such as N-methyl-D-aspartate receptor antagonists, have shown great promise in preclinical studies...
October 13, 2017: Translational Stroke Research
https://www.readbyqxmd.com/read/29023498/incidence-and-risk-factors-of-massive-subretinal-hemorrhage-in-retinal-angiomatous-proliferation
#9
Jae Hyung Lee, Mee Yon Lee, Won Ki Lee
OBJECTIVE: To evaluate the incidence and associated risk factors of massive subretinal hemorrhage (SRH) in patients with retinal angiomatous proliferation (RAP). METHODS: A total of 187 eyes of 135 treatment-naıve patients diagnosed with RAP were evaluated retrospectively. Clinical records including the time between the initial visit, last anti-vascular endothelial growth factor (VEGF) treatment, last stable examination, and the date of massive SRH were reviewed...
2017: PloS One
https://www.readbyqxmd.com/read/29021776/sex-differences-in-rt-pa-utilization-at-hospitals-treating-stroke-the-national-inpatient-sample
#10
Amelia K Boehme, Brendan G Carr, Scott Eric Kasner, Karen C Albright, Michael J Kallan, Mitchell S V Elkind, Charles C Branas, Michael T Mullen
BACKGROUND AND PURPOSE: Sex and race disparities in recombinant tissue plasminogen activator (rt-PA) use have been reported. We sought to explore sex and race differences in the utilization of rt-PA at primary stroke centers (PSCs) compared to non-PSCs across the US. METHODS: Data from the National (Nationwide) Inpatient Sample (NIS) 2004-2010 was utilized to assess sex differences in treatment for ischemic stroke in PSCs compared to non-PSCs. RESULTS: There were 304,152 hospitalizations with a primary diagnosis of ischemic stroke between 2004 and 2010 in the analysis: 75,160 (24...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28994833/the-efficacy-and-safety-of-endovascular-recanalization-of-occluded-large-cerebral-arteries-during-the-subacute-phase-of-cerebral-infarction-a-case-series-report
#11
Kangning Chen, Xianhua Hou, Zhenhua Zhou, Guangjian Li, Qu Liu, Li Gui, Jun Hu, Shugui Shi
BACKGROUND: Intravenous tissue plasminogen activator with or without mechanical thrombectomy during the acute phase are approved therapies for ischaemic stroke. Due to the short treatment time window (<6 hours) and often treatment failure, these patients would still have an intracranial arterial occlusion (IAO). It is unclear whether these patients can benefit from subsequent interventional recanalizationof their occluded artery in the subacute phase. In this retrospective study, we have examined the efficacy and safety in patients who have received either percutaneous transluminal angioplasty (PTA) or percutaneous transluminal angioplasty and stenting (PTAS) for IAO in the subacute phase of their stroke...
September 2017: Stroke and Vascular Neurology
https://www.readbyqxmd.com/read/28989804/the-chinese-stroke-association-scientific-statement-intravenous-thrombolysis-in-acute-ischaemic-stroke
#12
REVIEW
Qiang Dong, Yi Dong, Liping Liu, Anding Xu, Yusheng Zhang, Huaguang Zheng, Yongjun Wang
The most effective medical treatment for acute ischaemic stroke (AIS) is to offer intravenous thrombolysis during the ultra-early period of time after the onset. Even based on the Consensus of Chinese Experts on Intravenous Thrombolysis for AIS in 2012 and 2014 Chinese Guidelines on the Diagnosis and Treatment of AIS, the rate of thrombolysis for AIS in China remained around 2.4%, and the rate of intravenous tissue plasminogen activator usage was only about 1.6% in real world. The indication of thrombolysis for AIS has been expanded, and contraindications have been reduced with recently published studies...
September 2017: Stroke and Vascular Neurology
https://www.readbyqxmd.com/read/28988732/rupture-of-an-occult-intracranial-mycotic-aneurysm-after-intravenous-thrombolysis-with-recombinant-tissue-plasminogen-activator-for-acute-ischemic-stroke
#13
Jared Glenn, Margaret Strecker-McGraw, Ian McGraw, Karim Jabbar, Nathan A James, C Keith Stone
BACKGROUND: The treatment of acute ischemic stroke with recombinant tissue plasminogen activator (rtPA) has become the mainstay of treatment, but its use carries a risk of subsequent intracranial hemorrhage (ICH). Guidelines have been developed to aid in the selection of the appropriate candidates to treat with rtPA to reduce this risk. We present a case of a stroke patient who was an appropriate candidate and was treated with rtPA who experienced a fatal subarachnoid hemorrhage due to a ruptured mycotic aneurysm (MA)...
October 5, 2017: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/28986280/recombinant-tissue-plasminogen-activator-induces-long-term-anxiety-like-behaviors-via-the-erk1-2-gad1-gaba-cascade-in-the-hippocampus-of-a-rat-model
#14
Mei-Xue Dong, Chen-Meng Li, Peng Shen, Qing-Chuan Hu, You-Dong Wei, Yi-Fei Ren, Jia Yu, Si-Wen Gui, Yi-Yun Liu, Jun-Xi Pan, Peng Xie
OBJECTIVES: Recombinant tissue plasminogen activator (rtPA) is widely used for patients with thromboembolic disease, and increasing evidence indicates that it can directly induce neurotoxicity independent of its thrombolysis property. Here, we aimed to confirm the long-term effect of rtPA on animal's behavior, and investigate the underlying pathogenesis. METHODS AND RESULTS: Male Sprague-Dawley rats randomly received a dose of rtPA (10 mg/kg) or sterile saline...
October 3, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28983900/predicting-tissue-plasminogen-activator-use-and-success-in-in-center-hemodialysis-patients
#15
Sarah Daisy Kosa, Chenglin Ye, Lehana Thabane, Amiram Gafni, Charmaine E Lok
INTRODUCTION: Hemodialysis catheter malfunction is problematic. We aimed to determine clinical, catheter, and hemodialysis variables that predict: (i) catheter malfunction requiring recombinant tissue-plasminogen activator (TPA) treatment and (ii) the success of TPA administration. METHODS: Clinical, catheter, and hemodialysis variables were collected from a cohort of 559 catheters (141,526 catheter days) in 175 hemodialysis patients (2008-2011). Time to, and predictors of, catheter malfunction were determined for all catheters and primary catheters only, analyzed by Cox-proportional hazard model, multi-variable logistic regression model, and mixed-effect logistic regression models...
October 4, 2017: Journal of Vascular Access
https://www.readbyqxmd.com/read/28983488/neurovascular-function-recovery-after-focal-ischemic-stroke-by-enhancing-cerebral-collateral-circulation-via-peripheral-stimulation-mediated-interarterial-anastomosis
#16
Han-Chi Pan, Lun-De Liao, Yu-Chun Lo, Jia-Wei Chen, Han-Lin Wang, Li Yang, Yao-Wen Liang, Po-Yu Huang, Ming-Hsun Yang, You-Yin Chen
Current treatments for ischemic stroke have focused on the administration of a tissue plasminogen activator, although the associated side effects and subsequent reperfusion injury remain challenging. Peripheral electrical stimulation has shed light on therapeutic interventions for ischemia by increasing cerebral blood flow (CBF) to the target region through collateral circulation, although the mechanism remains elusive. Here, a focal photothrombotic ischemic (PTI) stroke was induced in the right hemispheric primary somatosensory forelimb cortex (S1FL) of rat brains, and the therapeutic effects of forelimb and hindlimb stimulation were characterized at the contralesional S1FL...
July 2017: Neurophotonics
https://www.readbyqxmd.com/read/28982834/how-biomarkers-reflect-the-prognosis-and-treatment-of-necrotising-soft-tissue-infections-and-the-effects-of-hyperbaric-oxygen-therapy-the-protocol-of-the-prospective-cohort-protreat-study-conducted-at-a-tertiary-hospital-in-copenhagen-denmark
#17
Peter Polzik, Pär I Johansson, Ole Hyldegaard
INTRODUCTION: Not enough is known regarding the prognosis and treatment of necrotising soft tissue infections (NSTIs). Mortality has been shown to be 25%-35%, with survivors coping with amputations and prolonged rehabilitation. This study will evaluate soluble urokinase-type plasminogen activator receptor (suPAR) as a possible prognostic marker of NSTI severity and mortality, as well as whether hyperbaric oxygen therapy (HBOT) can modulate markers of endothelial damage during NSTI. We hypothesise that in patients with NSTI, suPAR can provide prognostic risk assessment on hospital admission and that HBOT can reduce the endothelial damage that these patients are exposed to...
October 5, 2017: BMJ Open
https://www.readbyqxmd.com/read/28978008/upregulation-of-cftr-in-patients-with-endometriosis-and-its-involvement-in-nf%C3%AE%C2%BAb-upar-dependent-cell-migration
#18
Wenqing Huang, Aihong Jin, Jieting Zhang, Chaoqun Wang, Lai Ling Tsang, Zhiming Cai, Xiaping Zhou, Hao Chen, Hsiao Chang Chan
Endometriotic tissues exhibit high migration ability with the underlying mechanisms remain elusive. Our previous studies have demonstrated that cystic fibrosis transmembrane conductance regulator (CFTR) acts as a tumor suppressor regulating cell migration. In the present study, we explored whether CFTR plays a role in the development of human endometriosis. We found that both mRNA and protein expression levels of CFTR and urokinase-type plasminogen activator receptor (uPAR) were significantly increased in ectopic endometrial tissues from patients with endometriosis compared to normal endometrial tissues from women without endometriosis and positively correlated...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28976409/subdural-instillation-of-a-thrombolytic-agent-for-treatment-of-recurrent-subdural-hematoma
#19
Mark B Frenkel, Aarti Sarwal, Mary Petrulis Wren, Christopher R Newey, Daniel E Couture
OBJECTIVE: This study aims to report the case of a patient with recurrent subdural hemorrhage (SDH) who was administered tissue plasminogen activator through a subdural drain to enhance drainage and prevent recurrence. METHODS: An 85-year-old man was treated for subacute over chronic SDH that kept on reaccumulating despite serial twist drill drainage, burr hole drainage, and craniotomy. No coagulopathy was identified with adequate blood pressure control. RESULTS: Treatment with tissue plasminogen activator resulted in successful drainage of the SDH, and the patient had no further recurrence at 9-month follow-up...
October 2, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28976017/early-administration-of-pyrrolidine-dithiocarbamate-extends-the-therapeutic-time-window-of-tissue-plasminogen-activator-in-a-male-rat-model-of-embolic-stroke
#20
Zhongxing Wang, Weiran Shan, Jiangbei Cao, Max Wintermark, Wenqi Huang, Zhiyi Zuo
Tissue plasminogen activator (tPA) is used in fewer than 4% of patients after ischemic stroke because of its narrow therapeutic time window. We tested whether pyrrolidine dithiocarbamate (PDTC), a drug with multiple mechanisms to provide neuroprotection, can be used to extend the therapeutic time window of tPA. Three-month-old male Sprague-Dawley rats were subjected to embolic stroke in the area supplied by the right middle cerebral artery. tPA at 10 mg/kg was given intravenously 4 h after the onset of stroke...
October 4, 2017: Journal of Neuroscience Research
keyword
keyword
762
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"